Earnings call transcript: Myomo beats Q1 2026 expectations, stock dips

Myomo beat Q1 2026 expectations with EPS of -$0.07 versus -$0.12 consensus and revenue of $10.1 million versus $9.24 million expected, while gross margin improved to 68.2% from 67.2%. Management raised confidence in its growth strategy, citing MyoConnect, payer-contract expansion, and international momentum, and guided Q2 revenue to $10.3 million-$10.8 million. Despite the beat, shares fell 2.98% after hours and another 1.93% in aftermarket trading, reflecting investor caution around ongoing losses and guidance durability.

Analysis

The key read-through is not the quarter itself, but the changing quality of demand. Myomo is shifting from expensive, low-intent direct response toward clinician-led referral channels, which should compress customer acquisition cost and raise conversion durability over the next 2-4 quarters. That mix shift also makes the business less binary: recurring referrals can compound faster than headline unit growth if each clinic begins sending repeat patients, so the real operating leverage may show up with a lag rather than immediately in the next print.

The market’s negative post-earnings reaction likely reflects skepticism that the current margin inflection is sustainable once advertising is re-accelerated and channel mix normalizes. That skepticism is rational, but it may miss the second-order effect that payer contracts and clinical education reduce authorization friction, which lowers not only CAC but also working-capital drag from slower claim resolution. If that conversion improvement holds, the enterprise value re-rating could come from lower cash burn, not just higher revenue, which matters more for a microcap with limited balance-sheet flexibility.

The biggest upside catalyst is evidence that MyoConnect becomes a repeatable referral flywheel rather than a one-time lead source. A few hundred active rehab sites plus national O&P distribution could materially change the growth curve by H2 2026/H1 2027, but the tail risk is reimbursement or channel execution stalling before that flywheel turns. In that case, the stock remains a funding-risk story, and any disappointment on pipeline conversion or margin sequentially would likely overwhelm modest revenue beats.

Contrarian view: the selloff may be overdone if investors are anchoring on near-term EPS instead of unit economics. In a company this small, a 100 bps gross margin improvement and lower cash use are more important than the reported loss, because they extend runway and increase the probability of reaching operating leverage before dilutive financing becomes necessary.

Key Decisions for Investors

• Speculative long MYO on weakness with a 3-6 month horizon: risk/reward improves if the market is over-discounting sequential margin normalization; trim aggressively if Q2 guidance comes in with softer referral conversion or higher-than-expected ad spend.
• Use call spreads instead of stock for MYO exposure: buy 3-6 month upside calls financed with higher-strike sales to express a rerating thesis tied to recurring referrals, limiting downside if the microcap de-rates further on liquidity concerns.
• Pair trade: long MYO / short a broad healthcare equipment basket over 1-2 quarters, on the view that channel mix and payer-access improvements are company-specific rather than sector-wide; exit if authorization rates or backlog growth decelerate.
• Watch for a financing overhang: if cash burn stays above ~$2.5M per quarter, reduce exposure on any rally because dilution risk can cap upside even on operational improvement.